293 related articles for article (PubMed ID: 29288509)
1. Cancer immunotherapy: A need for peripheral immunodynamic monitoring.
Wang W; Xia X; Wu S; Guo M; Lie P; He J
Am J Reprod Immunol; 2018 Jun; 79(6):e12793. PubMed ID: 29288509
[TBL] [Abstract][Full Text] [Related]
2. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
3. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
5. Addressing cancer immunotherapy research in Iran: adoptive cell therapy on the horizon.
Khatami F; Torabi-Rahvar M; Kiani J; Naderi M; Ahmadbeigi N
Cytotherapy; 2018 Oct; 20(10):1227-1237. PubMed ID: 30266521
[TBL] [Abstract][Full Text] [Related]
6. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
7. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
Houot R; Schultz LM; Marabelle A; Kohrt H
Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
[TBL] [Abstract][Full Text] [Related]
8. Cancer Immunotherapy in Older Patients.
Marrone KA; Forde PM
Cancer J; 2017; 23(4):219-222. PubMed ID: 28731944
[TBL] [Abstract][Full Text] [Related]
9. Adapting conventional cancer treatment for immunotherapy.
Qiao J; Liu Z; Fu YX
J Mol Med (Berl); 2016 May; 94(5):489-95. PubMed ID: 26910191
[TBL] [Abstract][Full Text] [Related]
10. [Basics of cancer immunotherapy].
Fujioka Y; Nishikawa H
Rinsho Ketsueki; 2016; 57(11):2346-2354. PubMed ID: 27941285
[TBL] [Abstract][Full Text] [Related]
11. Future Research Goals in Immunotherapy.
Hulett TW; Fox BA; Messenheimer DJ; Marwitz S; Moudgil T; Afentoulis ME; Wegman KW; Ballesteros-Merino C; Jensen SM
Surg Oncol Clin N Am; 2019 Jul; 28(3):505-518. PubMed ID: 31079803
[TBL] [Abstract][Full Text] [Related]
12. [New immunotherapeutic approaches in oncology and hematology].
Kroemer M; Turco C; Galaine J; Deschamps M; Limat S; Borg C
Transfus Clin Biol; 2015 Aug; 22(3):132-40. PubMed ID: 26068883
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy and immunomonitoring (CITIM): redefining cancer therapy.
Malyguine A; Umansky V; Shurin MR
J Immunotoxicol; 2009 Dec; 6(4):205-8. PubMed ID: 19908938
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in therapeutic antibodies for cancer immunotherapy.
Lee A; Sun S; Sandler A; Hoang T
Curr Opin Chem Biol; 2018 Jun; 44():56-65. PubMed ID: 29885949
[TBL] [Abstract][Full Text] [Related]
15. Microbial biomarkers for immune checkpoint blockade therapy against cancer.
Adachi K; Tamada K
J Gastroenterol; 2018 Sep; 53(9):999-1005. PubMed ID: 30003334
[TBL] [Abstract][Full Text] [Related]
16. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
18. Emerging Opportunities and Challenges in Cancer Immunotherapy.
Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
[TBL] [Abstract][Full Text] [Related]
19. Advances of ultrasound in tumor immunotherapy.
Lin J; Wu Y; Liu G; Cui R; Xu Y
Int Immunopharmacol; 2024 Jun; 134():112233. PubMed ID: 38735256
[TBL] [Abstract][Full Text] [Related]
20. [Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy].
Hatae R; Chamoto K
Rinsho Ketsueki; 2016; 57(10):2224-2231. PubMed ID: 27795534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
